Stockreport

Affimed Presents Data from Phase 1b Combination Study of AFM13 with Pembrolizumab at ASH

Affimed N.V.  (AFMD) 
Last affimed n.v. earnings: 11/19 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: affimed.com/investor-relations.php
PDF Completed dose-escalation shows combination of AFM13 and pembrolizumab is well-tolerated; 3-month ORR compares favorably to historical ORR of pembrolizumab alone Add [Read more]